Terns Pharmaceuticals Inc (TERN)
5.09
+0.04
(+0.79%)
USD |
NASDAQ |
May 01, 16:00
5.08
-0.01
(-0.20%)
Pre-Market: 09:05
Terns Pharmaceuticals Enterprise Value: 65.64M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 65.64M |
| April 30, 2024 | 63.05M |
| April 29, 2024 | 66.28M |
| April 26, 2024 | 54.00M |
| April 25, 2024 | 36.54M |
| April 24, 2024 | 43.66M |
| April 23, 2024 | 39.78M |
| April 22, 2024 | 48.18M |
| April 19, 2024 | 31.37M |
| April 18, 2024 | 33.31M |
| April 17, 2024 | 30.08M |
| April 16, 2024 | 38.48M |
| April 15, 2024 | 63.70M |
| April 12, 2024 | 68.87M |
| April 11, 2024 | 74.04M |
| April 10, 2024 | 75.98M |
| April 09, 2024 | 94.73M |
| April 08, 2024 | 92.79M |
| April 05, 2024 | 84.39M |
| April 04, 2024 | 91.50M |
| April 03, 2024 | 124.47M |
| April 02, 2024 | 165.85M |
| April 01, 2024 | 195.59M |
| March 28, 2024 | 160.68M |
| March 27, 2024 | 134.81M |
| Date | Value |
|---|---|
| March 26, 2024 | 134.81M |
| March 25, 2024 | 151.62M |
| March 22, 2024 | 163.26M |
| March 21, 2024 | 160.03M |
| March 20, 2024 | 159.38M |
| March 19, 2024 | 125.76M |
| March 18, 2024 | 129.97M |
| March 15, 2024 | 202.05M |
| March 14, 2024 | 170.37M |
| March 13, 2024 | 194.29M |
| March 12, 2024 | 197.53M |
| March 11, 2024 | 216.92M |
| March 08, 2024 | 260.89M |
| March 07, 2024 | 240.26M |
| March 06, 2024 | 265.44M |
| March 05, 2024 | 207.32M |
| March 04, 2024 | 217.01M |
| March 01, 2024 | 208.62M |
| February 29, 2024 | 209.26M |
| February 28, 2024 | 220.24M |
| February 27, 2024 | 252.53M |
| February 26, 2024 | 224.76M |
| February 23, 2024 | 261.57M |
| February 22, 2024 | 247.36M |
| February 21, 2024 | 258.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-113.35M
Minimum
May 11 2022
808.72M
Maximum
Mar 19 2021
122.23M
Average
76.13M
Median
Enterprise Value Benchmarks
| Viking Therapeutics Inc | 7.465B |
| Eli Lilly and Co | 761.94B |
| Pfizer Inc | 211.91B |
| Amgen Inc | 202.32B |
| Madrigal Pharmaceuticals Inc | 3.661B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.02M |
| Total Expenses (Quarterly) | 24.06M |
| EPS Diluted (Quarterly) | -0.29 |
| Earnings Yield | -24.95% |